A new car vs. health insurance? Average family job-based coverage hits $27,000

Job-based family health insurance premiums are projected to surge 6% in 2025 to an average of $26,993 annually, marking the steepest increase in two decades and the third consecutive year of such rises, according to a KFF survey. Driven by escalating drug and hospital costs, this trend, which now sees average family coverage rivaling the price of a new Toyota Corolla hybrid, is forcing employers to consider cutting coverage for expensive GLP-1 weight-loss medications and to shift more financial burden onto employees, raising concerns about worker affordability and the sustainability of current benefit structures.

Analysis

Job-based family health insurance premiums are projected to surge 6% in 2025 to an average of $26,993 annually, marking the steepest increase in two decades and the third consecutive year of such rises. This 26% increase over the last five years has outpaced general inflation (24%) but lagged workers' wage growth (29%). The average cost now rivals a new Toyota Corolla hybrid, highlighting the significant financial burden on families.

The primary drivers of these escalating costs are rising drug and hospital expenses, which show no signs of abating. Employers are increasingly concerned about the high price of GLP-1 weight-loss medications, leading some to tighten or eliminate coverage for these drugs. This indicates a potential shift in employer-sponsored benefit structures and a direct impact on pharmaceutical demand for certain high-cost therapies.

Employers typically respond by shifting costs to workers, with nearly half of large employers reporting "moderate" or "high" employee concerns about cost-sharing. Furthermore, the ongoing federal shutdown and potential expiration of ACA tax credits could exacerbate the situation, doubling premiums for 22 million individuals and potentially increasing the uninsured population due to Medicaid cuts. This broader policy uncertainty adds significant risk to the healthcare landscape and consumer financial stability.

Key Decisions for Investors

• Monitor companies with significant U.S. employee bases for potential margin pressure due to rising healthcare costs.
• Evaluate the demand outlook for high-cost pharmaceuticals, particularly GLP-1 drugs, as employer coverage tightens.
• Assess the impact of increasing out-of-pocket healthcare expenses on consumer discretionary spending and retail sectors.
• Track legislative developments regarding ACA funding and Medicaid cuts for their potential systemic effects on the healthcare industry.